Teva Pharmaceuticals Europe BV, a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and MSD (known as Merck in the United States and Canada) (NYSE:MRK) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for NOMAC-E2 (nomegestrol acetate 2.5 mg /17β-estradiol 1.5 mg) an investigational monophasic combined oral contraceptive (COC) tablet indicated for the use by women to prevent pregnancy...
No comments:
Post a Comment